Times Argus

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
BioSpace

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
eLife

Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration

This important work advances our understanding of factors influencing efficacy assessments and biomarker viability for complement-directed gene therapy against age-related macular degeneration. The ...
Business Wire

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key activator of the ...
The American Journal of Managed Care

Type 1 Diabetes Onset Tied to Decreased Complement Protein Levels

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...
Frontiers

Local and Systemic Concentrations of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases

Background: The role of the lectin pathway of complement in the pathogenesis of interstitial lung diseases (ILDs) is largely unknown. Pattern recognition receptors (PRR) of the lectin pathway are ...
Business Wire

International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury

SEATTLE-- (BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded €1 ...